Psoriasis Patents (Class 514/863)
-
Patent number: 5976556Abstract: Novel compositions comprising one or more of an acid protease and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient, useful for treating or preventing abnormal biological conditions, diseases or disorders, and/or for improving the texture or appearance of the skin, and/or for enhancing epidermal exfoliation and/or for enhancing epidermal cell renewal and to methods for the use of the compositions. The acid protease comprises one or more proteolytic enzymes which exhibit proteolytic activity at pH values below that of the surface of the skin, i.e., approximately pH 5.5. The acidic buffer comprises inorganic and/or organic acids or mixtures thereof with a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient. The buffer is capable of reducing the pH of the surface of the skin to less than pH 5.5 and is susceptible to neutralization by normal epidermal processes.Type: GrantFiled: June 13, 1996Date of Patent: November 2, 1999Assignee: Active Organics, Inc.Inventors: Scott J. Norton, Michael A. Bishop, Glen S. Gillis
-
Patent number: 5976505Abstract: A method of cryogenically treating psoriatic lesions. In accordance with the present method, a cryogenic agent is applied by the spray technique to the surface of a psoriatic lesion for a period of time sufficient to "frost" the psoriatic lesion with the duration stopping short of the time necessary to cause formation of a fluid bullae or sloughing off of the affected tissue.Type: GrantFiled: July 2, 1997Date of Patent: November 2, 1999Assignee: HCS TrustInventor: R. Winn Henderson
-
Patent number: 5973010Abstract: A composition and method for treating epidermal wounds utilizes an aqueous solution of sodium sulphate, sodium carbonate, sodium bicarbonate, sodium chloride and ichthammol.Type: GrantFiled: May 15, 1998Date of Patent: October 26, 1999Inventor: Robert L. Crawford
-
Patent number: 5958432Abstract: Cosmetic/pharmaceutical compositions, well suited for the treatment of a variety of mammalian disorders of, for example, the skin, hair and/or mucous membranes, a manifestation of which is an excess in the synthesis and/or in the release of substance P, e.g., for the treatment of cutaneous disorders and sensitive skin, comprise an effective substance P antagonist amount of at least one .beta.-adrenergic agonist, e.g., salbutamol, in a cosmetically/pharmaceutically acceptable medium therefor.Type: GrantFiled: October 23, 1996Date of Patent: September 28, 1999Assignee: Societe L'Oreal S.A.Inventors: Lionel Breton, Olivier de Lacharriere, Jacques Leclaire
-
Patent number: 5955067Abstract: A composition is disclosed which is useful in alleviating, at least in part, symptoms of acne vulgaris, psoriasis or seborrhea, which includes a potassium-based compound a dermatologically acceptable base for the potassium-based compound, which is preferably a potassium salt, and which include potassium acetate, potassium aluminate, potassium arsenite solution, potassium bicarbonate, potassium bisulfate potassium bitartararte, potassium bromide, potassium carbonate, potassium chloride, potassium citrate, potassium gluconate, potassium glycerophosphate, potasium iodate, potassium iodide, potassium manganate, potassium permanganate, potassium phosphate monobasic potassium phosphate dibasic, potassium phosphate tribasic, potassium phosphite or a combination thereof. The composition is topically applied to the areas of a patient's skin which are afflicted with any of acne vulgaris, psoriasis or seborrhea.Type: GrantFiled: July 23, 1996Date of Patent: September 21, 1999Inventors: Eray Oge, Gary Goodwin
-
Patent number: 5955081Abstract: A psoriasis treatment composition derived from the plant Asphodelus Microcarpus includes 3-methylanthralin, chrysophanol, aloe-emodin, aloe-emodin monoacetate, and/or derivatives thereof. The composition is prepared by extracting a liquid from the Asphodelus Microcarpus root and mixing the liquid with acetic acid. A method of treatment includes applying the composition to an affected area of skin at a frequency sufficient to effect an alleviation of symptoms, typically once per day for 14-56 days.Type: GrantFiled: March 22, 1996Date of Patent: September 21, 1999Inventors: Marzook Moady, deceased, by Naseba Moady, heir
-
Patent number: 5955490Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignee: Queen's University at KingstonInventors: James C. Kennedy, Roy H. Pottier, Robert L. Reid, Arnold Sac-Morales, Lewis L. Tomalty
-
Patent number: 5955492Abstract: This invention relates to novel carboxylic acid indole compounds and compositions for use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).Type: GrantFiled: September 24, 1998Date of Patent: September 21, 1999Assignee: SmithKline Beecham CorporationInventors: Scott K. Thompson, Stacie M. Halbert, Katherine L. Widdowson
-
Patent number: 5952373Abstract: The invention relates to the use ofa) a compound or several compounds from the group consisting of flavonoidsb) of the antioxidants orc) of the endogenous energy metabolism metabolites ord) of the endogenous enzymatic antioxidant systems and synthetic derivatives thereof (mimics) ore) of the antimicrobial action systems orf) of the antiviral action systems org) active compounds of the known, conventional treatment formsin each case for the treatment or prophylactic treatment of hyperreactive skin predisposed to dermatitis or deficient, hypoactive skin or dermatoses.Type: GrantFiled: September 8, 1997Date of Patent: September 14, 1999Assignee: Beiersdorf AGInventors: Ghita Lanzendorfer, Franz Stab, Sven Untiedt
-
Patent number: 5948822Abstract: A method for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C26 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.Type: GrantFiled: November 25, 1997Date of Patent: September 7, 1999Assignee: Lidak PharmaceuticalsInventors: Laura E. Pope, Mohammed H. Khalil, John F. Marcelletti, Lee R. Katz, David H. Katz
-
Patent number: 5942231Abstract: A method of treating a patient suffering from allergic diseases, comprises administering to said patient an effective amount of a pharmaceutical composition in dosage unit form comprising a dry powder of guava leaves.Type: GrantFiled: June 18, 1996Date of Patent: August 24, 1999Assignee: O.S. Industry Co., Ltd.Inventors: Sadao Hamada, Susumu Kitanaka
-
Patent number: 5932622Abstract: A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5932229Abstract: Described are the use of compounds of Formula (I), depicted below, as active principals for treating skin conditions; compositions containing these compounds; and methods of treating skin conditions using these compounds and compositions. ##STR1## wherein R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 --C(.dbd.X.sub.2)X.sub.3 R.sub.11, n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, are independently, hydrogen or non-hydrogen substituents; and X, X.sub.1, X.sub.2, X.sub.3, Y and Z are independently, O, NH, or S.Type: GrantFiled: May 2, 1997Date of Patent: August 3, 1999Assignee: Avon Products, Inc.Inventors: Dmitri Ptchelintsev, Neil Scancarella, Robert Kalafsky
-
Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
Patent number: 5925376Abstract: An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D.sub.3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.Type: GrantFiled: August 24, 1995Date of Patent: July 20, 1999Inventor: Madalene C. Y. Heng -
Patent number: 5914334Abstract: The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.Type: GrantFiled: March 28, 1996Date of Patent: June 22, 1999Assignee: Allergan, Inc.Inventor: Prakash M. Charu
-
Patent number: 5902805Abstract: A method for the treatment of acne and/or the effects of ageing, by administering, to a subject in need thereof, a composition containing an effective amount of at least one HMG-Coenzyme A-reductase inhibitor in a carrier that is selected from the group consisting of dermatologically acceptable carriers, cosmetically acceptable carriers, and mixtures thereof, and the compositions for performing the method are provided.Type: GrantFiled: November 19, 1997Date of Patent: May 11, 1999Assignee: L'OrealInventors: Lionel Breton, Olivier De Lacharriere
-
Patent number: 5902827Abstract: Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of psoriasis.Type: GrantFiled: April 17, 1998Date of Patent: May 11, 1999Assignee: Cell PathwaysInventors: Rifat Pamukcu, Gary Piazza, Ewa Skopinska-Rozewska
-
Patent number: 5894019Abstract: A topically applicable pharmaceutical composition comprises at least one liquid lipid, at least one pharmaceutical active ingredient which is soluble in at least one of the liquid lipids and is re-absorbed by the skin, and a hydrous gel which is the main component of the composition, whereby at least one lipid and at least one active ingredient are worked into the gel and the composition is essentially free of emulsifying agents and solid constituents, with the exception of the necessary gelatinizing agent required to form the hydrous gel. All of the active ingredients are present in dissolved form, whereby at least one active ingredient is dissolved in the liquid lipid, and this lipid containing the dissolved active ingredient is itself the internal phase and is worked into the hydrous gel as the external phase. The composition is also essentially free of surface-active substances.Type: GrantFiled: September 17, 1997Date of Patent: April 13, 1999Assignee: GEBRO Broschek Gesellschaft m.b.H.Inventors: Ernst Hesse, Gerhard Hantich, Volker Eisenreich, Torsten Moller
-
Patent number: 5886038Abstract: A pharmaceutical composition for use in the treatment of psoriasis, having isopropyl myristate as its only active ingredient.Type: GrantFiled: March 24, 1998Date of Patent: March 23, 1999Assignees: Panda Pharmaceuticals, L.L.C., The University of Tennessee Research CorporationInventors: Thomas M. Glenn, E. William Rosenberg, Robert B. Skinner, Jr., Patricia W. Noah
-
Patent number: 5886053Abstract: The use of carotenoids for producing drugs for the treatment of inflammatory disorders not caused by the action of light or an infection with microorganisms.Type: GrantFiled: July 30, 1997Date of Patent: March 23, 1999Assignee: BASF AktiengesellschaftInventors: Wolfgang Schmutzler, Karl Kolter
-
Patent number: 5885557Abstract: This invention relates to compositions useful in the phototherapeutic treatment of psoriasis and other proliferative skin diseases. The compositions of the present invention comprise dihydroxyacetone and a penetration attenuator, both in a cosmetically and/or pharmaceutically acceptable carrier. Optionally, the compositions of the present invention may also contain an acidic component. The compositions of the present invention are useful in the exploitation during phototherapeutic treatment of the hyper-desquamation characteristics of the psoriatic or otherwise affected skin.Type: GrantFiled: February 8, 1996Date of Patent: March 23, 1999Assignee: Estee Lauder Inc.Inventor: Peter J. Lentini
-
Patent number: 5880101Abstract: The present invention relates to the use of at least one polyene macrolide for the preparation of pharmaceutical compositions for the treatment of diseases that are associated with an impaired energy turnover. Particularly, the present inventions allows to specifically stimulate the energy conversion in human cell, i.e. to stimulate the cell metabolism, and thus to treat or prevent a series of diseases.Type: GrantFiled: February 27, 1997Date of Patent: March 9, 1999Assignee: Dr. Zerle GmbHInventor: Georgi Stankov
-
Patent number: 5879711Abstract: Pharmaceutical compositions for the topical treatment of androgen-related conditions, e.g., acne in humans containing an amount of the compound represented by formula II effective for the topical treatment of the androgen-related conditions, e.g., acne ##STR1## dissolved in an alcohol-water solvent system, such as ethanol-water ?97.6:2.4(w/w)! and having an apparent pH in the range of about 3.5 to 4.5, and containing a gelling agent are disclosed.Type: GrantFiled: November 7, 1997Date of Patent: March 9, 1999Inventors: Joel A. Sequeira, Fernand Labrie, Shanshank Mahashabde, Nicholas DeAngelis, Yves Merand, Marc Fournier
-
Patent number: 5874071Abstract: Therapeutic treatment as well as prophylactic measures are provided by topical application of compositions containing an aryl 2-acetoxyethanoic acid to eradicate or prevent the development of axillary foul odor, foot malodor and other body odors, e.g. scalp, and skin, nail and follicular infections caused by microorganisms. The compositions are antimicrobial against several organisms that infect the skin and are specifically effective against P. acnes. The compositions are therapeutically effective against folliculitis and perifolliculitis and are useful for other skin lesions, nail and mucosal infections such as impetigo, seborrheic dermatitis, erythrasma and trichomycosis axillaris, associated with or caused by microorganisms. The therapeutic effect of the composition may be synergized or amplified by it incorporating a cosmetic or dermatologic agent into the formulation for topical treatment of cosmetic and dermatologic indications.Type: GrantFiled: June 30, 1998Date of Patent: February 23, 1999Assignee: TriStrata, Inc.Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 5871950Abstract: The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Inventors: Dinah S. Singer, Leonard Kohn, Edna Mozes, Motoyasu Saji, Jocelyn Weissman, Giorgio Napolitano, Fred D. Ledley
-
Patent number: 5869104Abstract: A method for the topical treatment of skin affected with a dermatological condition selected from the group consisting of impetigo, epidermolysis bullosa, eczema, neurodermatitis, psoriasis, pruritis, erythema, hidradenitis suppurativa, warts, diaper rash, jock itch, and combinations thereof. For most conditions, sodium chloride, in a substantially pure form as a solid block, is topically applied to the affected skin by gently gliding the block over the affected skin in a manner insufficient to cause abrasion and debridement of the affected skin. For certain conditions, such as epidermolysis bullosa, sodium chloride in the form of an aqueous solution preferably should be used. The applied sodium chloride is left on the skin.Type: GrantFiled: September 19, 1997Date of Patent: February 9, 1999Inventors: Lesli A. Taylor, Ralph L. Bass
-
Patent number: 5855922Abstract: Compositions and processes for the prophylaxis and therapeutic treatment of wounds, chronic non-healing wounds, burns, disease and other dermal disorders are disclosed. The compositions of the present invention comprise aqueous solutions of a metal chlorite having a concentration of from about 0.002% to about 0.5% by weight of metal chlorite. The process of the present invention comprises treating the dermal disorder with an aqueous solution of from about 0.002% to about 0.5% by weight of a metal chlorite. Wounds, chronic non-healing wounds, burns and other dermal disorders treated in this manner heal more quickly and with reduced scar formation. The antiseptic compositions and processes of the present invention exhibit anticollagenous activity such that the characteristics of the healed skin, such as elasticity and tensile strength, are similar to undamaged skin.Type: GrantFiled: December 7, 1995Date of Patent: January 5, 1999Assignee: Bio-Cide International, Inc.Inventors: Bobby C. Danner, Hampar L. Karageozian, James P. Ringo
-
Patent number: 5851543Abstract: A composition and method for treatment of skin. The composition comprises a pharmaceutically acceptable carrier containing a bilayer component having one or more polar terminus groups and one or more non-polar terminus groups separated from said polar terminus groups capable of penetrating the outer surface of the skin to form an aligned bilayer within the stratum corneum. The bilayer assists in the formation of bilayer lamellae that is believed to replicate the bilayer lamellae present in healthy skin. The composition is topically applied to the skin as often as is required.Type: GrantFiled: November 26, 1997Date of Patent: December 22, 1998Assignee: Shipley Company, L.L.C.Inventors: Donald R. Korb, Thomas Glonek, Jack V. Greiner
-
Patent number: 5843452Abstract: A composition for use in immunosuppression therapy is disclosed. The composition includes an immunosuppressant drug, such as cyclosporin A, and an ethanol extract of the root xylem of Tripterygium wilfordii. The extract is effective alone, or in combination with such an immunosuppressant, in the treatment of transplantation rejection. Also disclosed is a method of immunosuppression that includes administering to a subject a pharmaceutically effective amount of an immunosuppressant drug and an extract of the type above, in an amount effective to potentiate the action of the drug.Type: GrantFiled: June 2, 1994Date of Patent: December 1, 1998Assignee: Pharmagenesis, Inc.Inventors: Tien-Wen Tao Wiedmann, Jian Wang, Nathan B. Pliam, Hank C. K. Wuh
-
Patent number: 5840758Abstract: Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; A is selected from (a) optionally substituted alkylene, (b) optionally substituted cycloalkylene, (c) optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, (d) optionally substituted alkenylene and (e) ##STR2## X is absent or is alkylene; Z is selected from (a) hydrogen, (b) COM wherein M is selected from --OR.sup.4, --NR.sup.6 R.sup.7, and a pharmaceutically acceptable metabolically cleavable group, (c) --OR.sup.2, (d) tetrazolyl, (e) --CH(OR.sup.2)--CH.sub.2 OR.sup.8, (f) --CH(OR.sup.2)--CH.sub.2 --CH.sub.2 OR.sup.8, (g) --CH(OR.sup.2)--CH(OR.sup.8)--CH.sub.2 OR.sup.9, and (h).dbd.N--OR.sup.2 ; and R.sup.Type: GrantFiled: June 6, 1996Date of Patent: November 24, 1998Assignee: Abbott LaboratoriesInventors: Clint D. W. Brooks, Teodozyj Kolasa, Wendy Lee, Andrew O. Stewart
-
Patent number: 5830915Abstract: The invention provides compounds which are useful as inhibitors of matrix metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described in the claims, a stereoisomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester acyloxyamide, imide or derivative thereof.Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by matrix metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: August 26, 1997Date of Patent: November 3, 1998Assignee: The Procter & Gamble CompanyInventors: Stanislaw Pikul, Kelly Lynn McDow-Dunham, Biswanath De, Yetunde Olabisi Taiwo
-
Patent number: 5821260Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignee: Emory UniversityInventors: Russell M. Medford, Margaret K. Offermann, R. Wayne Alexander, Sampath Parthasarathy
-
Patent number: 5817675Abstract: 8-Hydroxyquinoline is useful in the topical treatment of inflammatory proliferative skin diseases, especially psoriasis. It should be applied from an essentially anhydrous vehicle.Type: GrantFiled: May 27, 1997Date of Patent: October 6, 1998Assignee: Diomed Developments LimitedInventor: Martin Whitefield
-
Patent number: 5811101Abstract: A composition for treating acne and related skin conditions which contains salicylic acid and aloe vera which is improved by the addition of an effective amount of a methylxanthine. Preferably, the methylxanthine is derived from mate extract. A method for treating acne with the composition is also provided.Type: GrantFiled: April 29, 1997Date of Patent: September 22, 1998Assignee: Waltman Pharmaceuticals IncorporatedInventor: Herschel Waltman
-
Patent number: 5811449Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5807600Abstract: The cutaneous atrophy associated with the use of steroids topically can be ameliorated using salts of certain .alpha.-hydroxyacids.Type: GrantFiled: June 7, 1995Date of Patent: September 15, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Prakash Parab, Robert Lavker, James Leyden
-
Patent number: 5800831Abstract: The present invention is directed to a topical composition for the treatment of psoriasis. The composition comprises a film forming agent, a plasticizer, an aqueous alcoholic solution and an amount of alkali effective to prevent the gellation of the film forming agent. Vinyl acetate crotonic acid copolymer and poly(vinyl)acetate are especially preferred film-forming agents.Type: GrantFiled: April 1, 1996Date of Patent: September 1, 1998Assignee: Pfizer Inc.Inventors: Debbie L. Burnett, Victor M. Wong, Darius D. Dubash, Athanasios S. Ladas
-
Patent number: 5792787Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: August 11, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Margaret K. Offermann
-
Patent number: 5789445Abstract: Topical application to regions of tissue scarring of a composition comprising several ingredients commonly used in cosmetic products, such as benzoyl peroxide, leads to a reduction and a softening of scar tissue.Type: GrantFiled: April 9, 1997Date of Patent: August 4, 1998Inventor: Raymond H. Schweiger
-
Patent number: 5783201Abstract: Vitamin B12 is used to stimulate heme oxygenase production. In turn, levels of the molecules 12(R)-HETE and 12(R)-DIHETE, which are arachidonic acid derivatives, are reduced. Various topical formulations containing vitamin B12, but no other vitamins, are described.Type: GrantFiled: April 3, 1997Date of Patent: July 21, 1998Assignee: Hemogen, Inc.Inventors: Richard D. Levere, Nadar G. Abraham, Michal L. Schwartzman, Michael W. Dunn
-
Patent number: 5783596Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: July 21, 1998Assignee: Emory UniversityInventors: Russell M. Medford, Margaret K. Offermann, R. Wayne Alexander, Sampath Parthasarathy
-
Patent number: 5776973Abstract: Novel palladium complexes and pharmaceutical compositions comprising the same are provided. Such complexes comprise (palladium).sub.m (lipoic acid).sub.n, wherein m and n are each independently 1 or 2. A process for preparing such complexes is also disclosed. In addition, a method of treatment of tumors and a method of treatment of psoriasis comprising administering the pharmaceutical compositions of the present invention are provided.Type: GrantFiled: October 18, 1995Date of Patent: July 7, 1998Inventor: Merrill Garnett
-
Patent number: 5773231Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5773209Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5763487Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.Type: GrantFiled: January 22, 1996Date of Patent: June 9, 1998Assignee: Centre International de Recherches Dermatologiques GaldermaInventor: Jean-Michel Bernardon
-
Patent number: 5759550Abstract: An improved method for suppressing xenograft rejection in a host subject is disclosed. The method includes administering an immunosuppressant drug, where the drug or the amount of drug administered is, by itself, ineffective to suppress xenograft rejection. Effective xenograft suppression is achieved by also administering an ethanolic extract of Triterygium wilfordii or a purified triptolide component thereof.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignee: Pharmagenesis, Inc.Inventors: Tien Wen Tao Wiedmann, Jian Wang
-
Patent number: 5760006Abstract: The use of compounds of the following formula I: ##STR1## for treating psoriasis is disclosed.Type: GrantFiled: June 23, 1997Date of Patent: June 2, 1998Assignee: Ortho Pharmaceutical CorporationInventors: Richard P. Shank, Claudia K. Derian
-
Patent number: 5750351Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: May 12, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5747482Abstract: Disclosed are methods to inhibit mammalian skin cell proliferation and, in particular, human keratinocyte proliferation by the topical administration of neutral gallium complexes.Type: GrantFiled: July 30, 1996Date of Patent: May 5, 1998Inventor: Lawrence R. Bernstein
-
Patent number: 5747064Abstract: The present invention is directed to a topical composition for the treatment of psoriasis. The composition comprises a film forming agent, especially vinyl acetate crotonic acid copolymer a plasticizer, an aqueous alcoholic solution and an amount of alkali effective to prevent the gellation of the film forming agent.Type: GrantFiled: July 17, 1997Date of Patent: May 5, 1998Assignee: Pfizer Inc.Inventors: Debbie L. Burnett, Darius D. Dubash, Athanasios S. Ladas, Victor M. Wong